The 3 arms of the "recover-vital" portion of the NIH trial are testing a 25 day regimen of paxlovid, a 15 day regimen with 10 days ritonavir, vs ritonavir plus placebo for 25 days I have no idea why the 15 day course only has 10 days of booster. Seems like that could be a setup for paxlovid resistance if someone on this regimen contracts covid along the way while being given a subtherapeutic dose. Even the 25 day arm could get infection since the drug failed to prevent transmission in household contacts I guess, but I don't understand giving the virus exposure to low dose of the active agent - i mean that is how resistance is bred in a lab I thought?
News 
Market Data 
Discover 
